Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. 1996

T Wada, and H Yokoyama, and S B Su, and N Mukaida, and M Iwano, and K Dohi, and Y Takahashi, and T Sasaki, and K Furuichi, and C Segawa, and Y Hisada, and S Ohta, and K Takasawa, and K Kobayashi, and K Matsushima
First Department of Internal Medicine, School of Medicine, Kanazawa University, Japan.

Monocytes/macrophages (M phi) have been implicated in the pathogenesis of lupus nephritis (LN), but the precise molecular mechanism of recruitment and activation of M phi in LN remains unclear. To clarify the involvement of chemotactic cytokines (chemokines) in those events, we measured levels of monocyte chemotactic and activating factor (MCAF, also termed monocyte chemoattractant protein-1, MCP-1) in urines and sera derived from 42 patients with LN. Both urinary and serum MCAF levels were significantly higher in patients with LN as compared with 22 healthy volunteers (10.3 +/- 3.2 vs. 1.0 +/- 0.1 pg/ml . creatinine, 212.2 +/- 75.8 vs. 66.1 +/- 15.5 pg/ml, respectively, P < 0.05, mean +/- SEM). Histological examination of renal lesions from 41 patients classified 19 as active according to the WHO-defined classes IIIb, IVb and IVc, and 22 as inactive by the WHO-defined classes I, II, IIIc, IVd and V. Urinary MCAF levels in the patients with active lesions were significantly higher than those with inactive lesions (20.3 +/- 6.4 vs. 1.7 +/- 0.3 pg/ml . creatinine, P < 0.01). Moreover, elevated urinary MCAF levels were dramatically decreased during steroid therapy-induced convalescence in 29 patients examined serially (13.9 +/- 4.5 vs. 5.3 +/- 1.7 pg/ml . creatinine, P < 0.001), whereas serum MCAF levels did not change significantly. Endothelial cells, renal epithelial cells and infiltrating mononuclear cells in the tubulointerstitial regions were MCAF-positive in immunohistochemical as well as in situ hybridization analysis. These observations suggest that MCAF is probably involved in the pathogenesis of LN with active lesions, possibly through the recruitment and activation of M phi, and that measurement of urinary MCAF levels may be a useful clinical tool for monitoring the disease activity of LN.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008181 Lupus Nephritis Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982). Glomerulonephritis, Lupus,Lupus Glomerulonephritis,Nephritis, Lupus,Glomerulonephritides, Lupus,Lupus Glomerulonephritides,Lupus Nephritides,Nephritides, Lupus
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

T Wada, and H Yokoyama, and S B Su, and N Mukaida, and M Iwano, and K Dohi, and Y Takahashi, and T Sasaki, and K Furuichi, and C Segawa, and Y Hisada, and S Ohta, and K Takasawa, and K Kobayashi, and K Matsushima
November 2010, Pediatric nephrology (Berlin, Germany),
T Wada, and H Yokoyama, and S B Su, and N Mukaida, and M Iwano, and K Dohi, and Y Takahashi, and T Sasaki, and K Furuichi, and C Segawa, and Y Hisada, and S Ohta, and K Takasawa, and K Kobayashi, and K Matsushima
May 1996, FEMS immunology and medical microbiology,
T Wada, and H Yokoyama, and S B Su, and N Mukaida, and M Iwano, and K Dohi, and Y Takahashi, and T Sasaki, and K Furuichi, and C Segawa, and Y Hisada, and S Ohta, and K Takasawa, and K Kobayashi, and K Matsushima
January 2022, Open access rheumatology : research and reviews,
T Wada, and H Yokoyama, and S B Su, and N Mukaida, and M Iwano, and K Dohi, and Y Takahashi, and T Sasaki, and K Furuichi, and C Segawa, and Y Hisada, and S Ohta, and K Takasawa, and K Kobayashi, and K Matsushima
March 2018, Clinical science (London, England : 1979),
T Wada, and H Yokoyama, and S B Su, and N Mukaida, and M Iwano, and K Dohi, and Y Takahashi, and T Sasaki, and K Furuichi, and C Segawa, and Y Hisada, and S Ohta, and K Takasawa, and K Kobayashi, and K Matsushima
September 2023, Archives of rheumatology,
T Wada, and H Yokoyama, and S B Su, and N Mukaida, and M Iwano, and K Dohi, and Y Takahashi, and T Sasaki, and K Furuichi, and C Segawa, and Y Hisada, and S Ohta, and K Takasawa, and K Kobayashi, and K Matsushima
January 2012, Indian journal of nephrology,
T Wada, and H Yokoyama, and S B Su, and N Mukaida, and M Iwano, and K Dohi, and Y Takahashi, and T Sasaki, and K Furuichi, and C Segawa, and Y Hisada, and S Ohta, and K Takasawa, and K Kobayashi, and K Matsushima
January 1991, Life sciences,
T Wada, and H Yokoyama, and S B Su, and N Mukaida, and M Iwano, and K Dohi, and Y Takahashi, and T Sasaki, and K Furuichi, and C Segawa, and Y Hisada, and S Ohta, and K Takasawa, and K Kobayashi, and K Matsushima
July 1989, Kidney international,
T Wada, and H Yokoyama, and S B Su, and N Mukaida, and M Iwano, and K Dohi, and Y Takahashi, and T Sasaki, and K Furuichi, and C Segawa, and Y Hisada, and S Ohta, and K Takasawa, and K Kobayashi, and K Matsushima
December 2019, Antioxidants & redox signaling,
T Wada, and H Yokoyama, and S B Su, and N Mukaida, and M Iwano, and K Dohi, and Y Takahashi, and T Sasaki, and K Furuichi, and C Segawa, and Y Hisada, and S Ohta, and K Takasawa, and K Kobayashi, and K Matsushima
January 2015, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia,
Copied contents to your clipboard!